title: Capecitabine in pretreated metastatic cholangiocarcinoma. A case report and review of the literature.
abstract: Cholangiocarcinoma is one of the most aggressive malignancies. Patients with advanced or metastatic disease have a particularly dismal prognosis. The role of chemotherapy remains a matter of debate. A number of recent trials have shown that capecitabine in combination with other agents seems to be active as first-line treatment in advanced biliary cancer. Clinical data regarding the activity of capecitabine in pretreated patients are limited. In this report we describe a patient with previously treated, metastatic cholangiocarcinoma who developed stabilization of the disease for 7 months following chemotherapy with capecitabine. The patient had previously received 2 lines of chemotherapy. Capecitabine was tolerated fairly well without serious adverse events. We consider this observation to be important given the absence of active, non-surgical treatments in unresectable tumors.
authors.affiliation: Division of Oncology, Department of Medicine, University Hospital, Patras Medical School, Rion, Greece. angkoutr@otenet.gr
authors.forename: A K
authors.initials: AK
authors.lastname: Koutras
authors.forename: G
authors.initials: G
authors.lastname: Talampuka
authors.forename: N
authors.initials: N
authors.lastname: Pagoni
authors.forename: K C
authors.initials: KC
authors.lastname: Thomopoulos
authors.forename: G
authors.initials: G
authors.lastname: Kalliolias
authors.forename: C
authors.initials: C
authors.lastname: Kalogeropoulou
authors.forename: H P
authors.initials: HP
authors.lastname: Kalofonos
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D001650:Bile Duct Neoplasms / Q000188:drug therapy*; D000069287:Capecitabine; D002272:Carcinoembryonic Antigen / Q000097:blood; D018281:Cholangiocarcinoma / Q000188:drug therapy* / Q000556:secondary; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D000964:Antimetabolites, Antineoplastic; D002272:Carcinoembryonic Antigen; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil